Advanced Search Abstract Background: With the increased usage of neoadjuvant chemoradiotherapy, improved surgical technique and stapling devices, sphincter-preserving resection has become more frequent for patients with rectal cancer. However, as for locally advanced ultra-low rectal cancer, sphincter-preservation is still facing an enormous challenge. To introduce an NLT strategy of sphincter-preservation—neoadjuvant therapy NT followed by local excision LE and two-stage total mesorectal excision TME —into the treatment of locally advanced ultra-low rectal cancer lesions with anal sphincter invasion. From October to October , nine patients with locally advanced rectal cancer located less than 3 cm from the anal verge were treated by the NLT strategy.
There was a problem providing the content you requested
Novel Treatment Options for Fecal Incontinence
Abstract Fecal incontinence FI is a devastating condition affecting a substantial portion of the population. The etiologies of FI are wide ranging, as are the treatment options. When conservative measures fail, often surgical intervention is required. As in any area where a wide range of treatment options exist, there is no one perfect solution. Fortunately, novel treatment options for FI are becoming available, namely, posterior tibial nerve stimulation, magnetic anal sphincter, stem cell transplant, pyloric transplantation, and acupuncture. The reader should be able to define and explain the utility of the less common and more novel treatment modalities for fecal incontinence, including posterior tibial nerve stimulation, the magnetic anal sphincter, stem cell transplant, and acupuncture. Comparison to more common treatments can be made.
In order to improve the overall survival OS and disease-free survival DFS , we added oxaliplatin to the standard treatment, and compared the effectiveness of these two treatment patterns. They were randomized into the experimental group received oxaliplatin and capecitabine in combination with radiotherapy, and the control group received capecitabine in combination with radiotherapy. The primary endpoints were DFS and OS, and the secondary endpoints included toxicity, compliance, and histopathological response.